Helicobacter pylori is associated with a higher risk of MAFLD prevalence and all-cause mortality: results from the NHANES III follow-up study

Abstract

Aim: This study examined the relationship between Helicobacter pylori (H. pylori) and metabolic dysfunction-associated fatty liver disease (MAFLD) and concurrently evaluated their association with all-cause mortality risk.

Methods: Data were extracted from the Third National Health and Nutrition Examination Survey, which included 5,073 participants with available H. pylori IgG serology [enzyme-linked immunosorbent assay (ELISA)] results and mortality data. Logistic regression was used to assess the relationship between H. pylori seropositivity and MAFLD risk, while Cox proportional hazards regression was used to evaluate all-cause mortality risk, with adjustment for confounders.

Results: Among 5,073 participants, 2,394 (47.2%) tested positive for H. pylori and 1,610 (31.7%) had MAFLD; during a median follow-up of 28.8 years, 1,891 deaths occurred (overall mortality rate 37.3%). H. pylori-seropositive individuals exhibited significantly higher mortality rates than seronegative individuals (43.5% vs. 31.7%, P < 0.001). Multivariate logistic regression confirmed H. pylori seropositivity as an independent risk factor for MAFLD [adjusted odds ratio (OR) = 1.282, 95% confidence interval (CI): 1.126-1.459, P < 0.001]. Multivariate Cox regression revealed that H. pylori seropositivity independently increased mortality risk (adjusted HR = 1.253, 95%CI: 1.139-1.379, P < 0.001), which was consistent across the MAFLD and non-MAFLD subgroups. Kaplan-Meier analysis corroborated significant survival divergence (log-rank, P < 0.001).

Conclusion: This study indicates that H. pylori seropositivity is independently associated with a higher prevalence of MAFLD and greater mortality risk in community-dwelling individuals.

Keywords

Helicobacter pylori / MAFLD / mortality / NHANES

References

[1] Li Y,Leung K,Graham DY.Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol2023;8:553-64

[2] Duan Y,Dou Y.Helicobacter pylori and gastric cancer: mechanisms and new perspectives.J Hematol Oncol2025;18:10 PMCID:PMC11756206

[3] Tsay FW.H. pylori infection and extra-gastroduodenal diseases.J Biomed Sci2018;25:65 PMCID:PMC6114542

[4] Yaslianifard S,Kazemi K.Beyond the gut: a comprehensive meta-analysis on Helicobacter pylori infection and cardiovascular complications.Ann Clin Microbiol Antimicrob2025;24:18 PMCID:PMC11916874

[5] Penaflorida JLGR,Romero KYB.Association between Helicobacter pylori and hepatobiliary cancer: a meta-analysis and systematic review.Asian Pac J Cancer Prev2024;25:3363-70 PMCID:PMC11711343

[6] Fabbri N,Pesce A,Romeo D.Role of Helicobacter pylori infection and the risk of cholelithiasis.World J Gastroenterol2025;31:102024 PMCID:PMC11886511

[7] Lazarus JV,Cortez-Pinto H.NAFLD - sounding the alarm on a silent epidemic.Nat Rev Gastroenterol Hepatol2020;17:377-9

[8] Riazi K,Charette JH.The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis.Lancet Gastroenterol Hepatol2022;7:851-61

[9] Estes C,Loomba R,Sanyal AJ.Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.Hepatology2018;67:123-33 PMCID:PMC5767767

[10] Guo W,Lu J.Diet and risk of non-alcoholic fatty liver disease, cirrhosis, and liver cancer: a large prospective cohort study in UK biobank.Nutrients2022;14:5335 PMCID:PMC9788291

[11] Mostafa AM,Yu ML,Fouad Y.MAFLD: a comprehensive review of the link between metabolic dysfunction and cardiovascular risk.Hepat Med2025;17:75-90 PMCID:PMC12374717

[12] Yuan X,Wu S.Associations between metabolic dysfunction-associated fatty liver disease and extrahepatic cancers: a cohort in China.Hepatobiliary Surg Nutr2023;12:671-81 PMCID:PMC10598323

[13] Dong TS,Lagishetty V.Gut microbiome profiles associated with steatosis severity in metabolic associated fatty liver disease.Hepatoma Res2021;7:37 PMCID:PMC9881202

[14] Heydari K,Alizadeh-Navaei R.Helicobacter pylori infection and non-alcoholic fatty liver disease: a systematic review and meta-analysis.Turk J Gastroenterol2022;33:171-81 PMCID:PMC9128487

[15] Gulati A,Lin J.Association between Helicobacter pylori infection, MASLD, and liver fibrosis in patients with severe obesity: a single-center experience.Surg Endosc2024;38:6873-9

[16] Liu Y,Zhao Z,Wang X.No evidence for a causal link between Helicobacter pylori infection and nonalcoholic fatty liver disease: A bidirectional Mendelian randomization study.Front Microbiol2022;13:1018322 PMCID:PMC9669663

[17] Eslam M,Sarin SK.A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement.J Hepatol2020;73:202-9

[18] Centers for Disease Control and Prevention. NHANES 1999-2000 Laboratory Methods. Available from https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/labmethods.aspx?BeginYear=1999. [accessed 4 June 2026].

[19] Centers for Disease Control and Prevention. Questionnaires, Datasets, and Related Documentation-NHANES III. Available from https://wwwn.cdc.gov/nchs/nhanes/nhanes3/datafiles.aspx. [accessed 4 June 2026].

[20] Wijarnpreecha K,Panjawatanan P,Jaruvongvanich V.Helicobacter pylori and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis.J Clin Gastroenterol2018;52:386-91

[21] Mantovani A,Altomari A.Association between Helicobacter pylori infection and risk of nonalcoholic fatty liver disease: an updated meta-analysis.Metabolism2019;96:56-65

[22] Xie J,Zeng R.Association between Helicobacter pylori infection and triglyceride levels: a nested cross-sectional study.Front Endocrinol2023;14:1220347 PMCID:PMC10468968

[23] Zhao MM,Cao X.Helicobacter pylori infection as a risk factor for serum bilirubin change and less favourable lipid profiles: a hospital-based health examination survey.BMC Infect Dis2019;19:157 PMCID:PMC6376701

[24] Mansori K,Naderpour S,Moghaddam AB.A systematic review and meta-analysis of the prevalence of Helicobacter pylori in patients with diabetes.Diabetes Metab Syndr2020;14:601-7

[25] Polyzos SA,Zavos C.The association between Helicobacter pylori infection and insulin resistance: a systematic review.Helicobacter2011;16:79-88

[26] Chen X,Peng D,Li R.Helicobacter pylori infection exacerbates metabolic dysfunction-associated steatotic liver disease through lipid metabolic pathways: a transcriptomic study.J Transl Med2024;22:701 PMCID:PMC11288106

[27] He C,Cheng D.Helicobacter pylori infection aggravates diet-induced insulin resistance in association with gut microbiota of mice.EBioMedicine2016;12:247-54 PMCID:PMC5078605

[28] Candelli M,Cianci R.The interplay between Helicobacter pylori and gut microbiota in non-gastrointestinal disorders: a special focus on atherosclerosis.Int J Mol Sci2023;24:17520 PMCID:PMC10744166

[29] Yu YY,Wu LY.Helicobacter pylori infection eradication for nonalcoholic fatty liver disease: a randomized controlled trial.Sci Rep2022;12:19530 PMCID:PMC9663549

[30] Jamali R,Vahedi H,Dowlatshahi S.The effect of Helicobacter pylori eradication on liver fat content in subjects with non-alcoholic Fatty liver disease: a randomized open-label clinical trial.Hepat Mon2013;13:e14679 PMCID:PMC3867002

[31] Kamboj AK,Oxentenko AS.Helicobacter pylori: the past, present, and future in management.Mayo Clin Proc2017;92:599-604

[32] Yildirim Z,Ozol D.Increased exhaled 8-isoprostane and interleukin-6 in patients with Helicobacter pylori infection.Helicobacter2016;21:389-94